Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Fragile X syndrome
- Focus Registrational; Therapeutic Use
- Acronyms CONNECT-FX
- Sponsors Zynerba Pharmaceuticals
- 11 Jan 2023 According to the Zynerba Pharmaceuticals media release, the company published the paper at the Journal of Neurodevelopmental Disorders describing the Role of the Endocannabinoid System in Fragile X Syndrome and mechanism to benefit from cannabidiol treatment which is supported by the results from this trial.
- 28 Nov 2022 According to a Zynerba Pharmaceuticals media release, data from this study were published in the Journal of Neurodevelopmental Disorders.
- 28 Nov 2022 Results published in the Zynerba Pharmaceuticals Media Release.